Amyotrophic Lateral Sclerosis (ALS): Epidemiology Report and Forecast

Amyotrophic Lateral Sclerosis (ALS): Epidemiology Report and Forecast

Summary

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disorder that affects the motor neurons in the brain and spinal cord responsible for voluntary muscle movement and breathing (National Institute of Neurological Disorders and Stroke, 2026). ALS typically manifests as either weakness in the limbs (spinal onset) or difficulty in speaking or swallowing (bulbar onset) (Longinetti & Fang, 2019). Eventually, people with ALS lose their ability to stand or walk, the use of their hands and arms, and ability to breathe, ultimately leading to death (National Institute of Neurological Disorders and Stroke, 2026). There is currently no cure or effective treatment for ALS to stop or reverse the progression of the disease (National Institute of Neurological Disorders and Stroke, 2026).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for ALS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of ALS. The diagnosed prevalent cases of ALS are segmented by age (18 years and older), sex, type of ALS (familial and sporadic), and genetic variant (SOD1, C9orf72, TARDP, and FUS). Additionally, the diagnosed incident cases of ALS are presented, for ages 18 and older, segmented by type (familial and sporadic). This report focuses on ALS, defined by International Statistical Classification of Diseases and Related Health Problems, 11th Revision (ICD-11) code 8B60.0, as well as patients diagnosed according to Gold Coast Criteria, supported by Revised El Escorial and Awaji Criteria. This definition is applied consistently across all markets. This epidemiology forecast for ALS is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed prevalent cases of ALS across these markets.

In the 8MM, the number of diagnosed prevalent cases is expected to increase by 7.09% over the forecast period at an annual growth rate (AGR) of 0.71%, from 81,143 cases in 2025 to 86,894 cases by 2035. In 2035, the US will have the highest number of diagnosed prevalent cases of ALS in the 8MM with 36,262 cases, and Spain will have the fewest diagnosed prevalent cases of ALS with 4,170 cases. In the 8MM, the number of diagnosed incident cases is expected to increase by 2.93% over the forecast period at an AGR of 0.29%, from 15,998 cases in 2025 to 16,466 cases by 2035. In 2035, the US will have the highest number of diagnosed incident cases of ALS in the 8MM with 5,296 cases, and Spain will have the fewest diagnosed incident cases of ALS with 761 cases. The analyst epidemiologists attribute the increase in diagnosed prevalent and diagnosed incident cases of ALS to changes in population dynamics, as well as the diagnosed incidence and prevalence in each market.

Scope

• The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Report and Forecast provide an overview of the risk factors, comorbidities, and global trends of ALS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, Canada).
• The report includes a 10-year epidemiology forecast of the diagnosed incident and prevalent cases of ALS in these markets from 2025-35. The diagnosed prevalent cases are further segmented by sex and age (18 and over). Diagnosed incident and prevalent cases were further segmented by ALS type (familial vs. sporadic). Diagnosed prevalent cases are further segmented by genetic variants, including SOD1, c9orf72, TARDP, and FUS.

Reasons to Buy

• The Amyotrophic Lateral Sclerosis Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global amyotrophic lateral sclerosis markets.
• Quantify patient populations in the global amyotrophic lateral sclerosis markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for amyotrophic lateral sclerosis therapeutics in each of the markets covered.
• Understand magnitude of the prevalent incident amyotrophic lateral sclerosis population by type.
• Understand magnitude of the prevalent diagnosed amyotrophic lateral sclerosis population by age, sex, type, and genetic variant.